You may have access to the free features available through My Research. You can save searches, save documents, create alerts and more. Please log in through your library or institution to check if you have access.
If you log in through your library or institution you might have access to this article in multiple languages.
Styles include MLA, APA, Chicago and many more. This feature may be available for free if you log in through your library or institution.
You may have access to it for free by logging in through your library or institution.
You may have access to different export options including Google Drive and Microsoft OneDrive and citation management tools like RefWorks and EasyBib. Try logging in through your library or institution to get access to these tools.
You might have access to the full article...
Try and log in through your institution to see if they have access to the full text.
The fully human lgG2 antibody ticilimumab* failed to demonstrate any benefit on overall survival as first-line treatment of patients with metastatic melanoma in a phase III study. These results were presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).
A total of 655 patients with unresectable stage IIIc-IV melanoma without brain metastasis were randomised to receive either IV ticilimumab 15 mg/kg...
